Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will present its EVA pharmaceutical material solutions at the 2016 AAPS Annual Meeting and Exposition November 13-17 at the Colorado Convention Center in Denver. Celanese will exhibit its pharmaceutical controlled release copolymer, VitalDose® ethylene vinyl acetate (EVA), at booth 1604.
Celanese material experts will discuss the latest developments in pharmaceutical material science and how EVA is being used in new drug delivery innovations. VitalDose® EVA controlled release excipients deliver reliable performance with customizable release properties that are compatible with many active pharmaceutical ingredients (APIs).
When formulating thermally sensitive APIs with excipients in the hot melt extrusion process, one of the major challenges is to make sure the APIs do not go through any thermal degradation. This will not only provide cost savings but also ensure the chemical integrity of the APIs during processing. Due to their intrinsic low melting points, broad melting ranges, and sheer thinning characteristics, EVA excipients provide outstanding low temperature processability along with their excellent controlled release properties and biocompatibility.
To help formulation scientists understand the processability temperature ranges of EVA excipients, Celanese has conducted experiments to show the minimum compounding temperatures of EVA excipients with vinyl acetate contents ranging from 9% to 40%. At AAPS, Celanese will demonstrate experiments of a tunable controlled release of Niacin with EVA excipients prepared by a low temperature hot melt extrusion process. The information provided with this original research will help formulation scientists better address the challenges in formulating thermally sensitive drugs by using EVA excipients.
Celanese will be presenting a poster session at the 2016 AAPS Annual Meeting and Exposition highlighting EVA’s processing advantages for drug formulators.
Celanese Poster Presentation:
|Presenter:||Dirk Hair, Technology & Innovation Manager – Product Development|
|Title:||Ethylene Vinyl Acetate Copolymer Excipients: Low Temperatures Extrusion Processability and Controlled Release|
|Date:||Tuesday, November 15, 2016|
“The unique properties of EVA controlled release excipients allow for customizable delivery rates that are expanding pharmaceutical possibilities,” said Susan Rahe, global business director of the Celanese EVA polymers business. “VitalDose® EVA offers flexible delivery systems and process versatility backed by high-touch technical expertise to assist from project conception through design and regulatory approval.”
For more information about Celanese’s controlled release pharmaceutical EVA polymer, VitalDose® EVA, please visit http://healthcare.celanese.com/.
Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit www.celanese.com or our blog at www.celaneseblog.com .
All registered trademarks are owned by Celanese International Corporation or its affiliates.
This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161111005101/en/Business Wire
Last updated on: 11/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.